Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
Transcript of Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
1/15
Ucl }loiagag`
}lzli}jc i`lgei2 f}kojkgu}kddle u}aidz uk
lffljuavl ~}k`}ioz
^}lzlgule mq2 ^al}}l Dijl}ul
Cliduc Ievazk} + Oiul}gid ige
Glpmk}g Cliduc ige G|u}auakg ^}k`}ioOigi`l} ag If}aji
Ecihi$ :}e Oiq $ =>9=
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
2/15
Mijh`}k|ge ige okuaviuakg fk} ucaz ~}lzlguiuakg
Lvaelgjl fk} ucl lffajijqkf jidja|o z|~~dlolguiuakg uk }le|jl }azh
kf ~}lljdio~zai az zu}kg` @lgl}iule f}ko }igekoarle jkgu}kddle u}aidz ag o|dua~dl zluuag`z
Fa}zu agul}vlguakgz zckpg uk ml lffljuavl fk} ~}lvlguakg
^i}uaj|di}dq }ldlvigu ag jkgulsu pcl}l lol}`lgjq kmzulu}aj ji}l
oiq ml plih'
Zqzuloiuaj }lvalpz uk ls~dk}l kvl}idd ao~iju fk}o mizaz kf
`|aeldaglz gkp elvldk~le mq PCK
I g|oml} kf ~}ijuajid y|lzuakgz }loiag$ igzpl}z uk pcajc pk|de
zu}lg`uclg ucl ji~ijauq uk elza`g ige ao~dlolgu ~}k`}ioz
Lvaelgjl mizl pk|de ml zu}lg`uclgle mq~}k`}io lvid|iuakgz$
jko~dlolgui}q uk uciu `lgl}iule ag }igekoarle u}aidz
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
3/15
Lsul}gid Fijuk}z
Zkjak/j|du|}id
Uljcgajid Ljkgkoaj
^kdauajid
^}kvazakg
Y|iguauq
Y|idauq
Uaoldaglzz
\~uihl
Ipi}lglzz
Iuuau|el
Ijjlzzamadauq
\uadariuakg
\~uihl ( Hgkpag` mlglfauz &
ckp uk |zl ( Lsul}gid
okuaviuakg
Ao~iju
G|u}auakgid Glle ( Jkvl}i`l ( \uadariuakg
Ao~iju kf agul}vlguakgz el~lgeigu kg o|dua~dl fijuk}z
Jkgulsu|iddq }ldlvigu ~ijhi`l kf agul}vlguakgz
Jkvl}i`l
^}kvazakg (
\~uihl mq uckzl ag
glle
GLLE
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
4/15
Kmbljuavlz kf ucaz ~}lzlguiuakg
Uk ls~dk}l zkol uk~ajz }ldiule uk jidja|o
z|~~dlolguiuakg uciu pk|de ml zu}lg`uclgle mq
ieeauakgid makdk`ajid ige ao~dlolguiuakg }lzli}jc
Uk agauaiul i eazj|zzakg kg i~~}k~}aiul piqz uk okvl
~}k`}ioz fk}pi}e pcadl ipiauag` ucaz ieeauakgid
lvaelgjl
Uk |~eiul kg zkol ievigjlz mlag` oiel kg ucl
}lzli}jc i`lgei
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
5/15
Zkol kf ucl jciddlg`lz uciu pl civl zllg fk} AFI
~}k`}ioz dahldq uk ml zaoadi} fk} Jidja|o
z|~~dlolguiuakg ~}k`}ioz
Eloige zael2
Jkguiju pauc pkolg oiq ml`ag kgdq diul ag ~}l`gigjq
A}}l`|di} jkguiju oiq daoau lffljuavl jkvl}i`l$
k~~k}u|gaualz fk} lgjk|}i`lolgu uk jko~dq ^kzzamdl azz|lz pauc |~uihl ige jko~daigjl
Z|~~dq zael2
M|e`lu iddkjiuakg ekgk} el~lgelgjq
^kk}dq f|gjuakgag` z|~~dq jciagz
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
6/15
Zkol kf ucl jciddlg`lz uciu pl civl zllg fk} AFI
~}k`}ioz dahldq uk ml zaoadi} fk} Jidja|o
z|~~dlolguiuakg ~}k`}ioz
Eloige zael2
Jkguiju pauc pkolg oiq ml`ag kgdq diul ag ~}l`gigjq
A}}l`|di} jkguiju oiq daoau lffljuavl jkvl}i`l$
k~~k}u|gaualz fk} lgjk|}i`lolgu uk jko~dq ^kzzamdl azz|lz pauc |~uihl ige jko~daigjl
Z|~~dq zael2
M|e`lu iddkjiuakg ekgk} el~lgelgjq
^kk}dq f|gjuakgag` z|~~dq jciagz
Iduck|`c pldd }ljk`garle$ oigq kf uclzlazz|lz civl gku mllg iely|iuldq iee}lzzle
fk} AFI ~}k`}ioz' Gkp pl zck|de2
Ivkae Ji ~}k`}ioz dahldq uk z|ffl} f}ko
zaoadi} z|~~dq ige eloige/zael ~}kmdloz
Uihl ievigui`l uk }lglp lffk}uz uk
zu}lg`uclg AFI ige Ji ~}k`}ioz
zao|duiglk|zdq
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
7/15'2'
OAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}io
Ieeauakgid jciddlg`lz
Aelguafajiuakg kf ~k~|diuakgz pauc dkp jidja|oaguihlz ag jkgulsu pcl}l ealui}q eiui az$ iu mlzu$
zji}jl
Jidja|o z|~~dlolguz oiq agcamau imzk}~uakg kfa}kg$ el~lgeag` kg ekzl ige a}kg zk|}jl
Jidja|o ige A}kg zci}l `izu}kagulzuagid zael lffljuz
uciu oa`cu daoau iecl}lgjl
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
8/15'2'
OAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}io
Zkol dlzzkgz dli}gu ige jkookg
zlgzl }lz~kgzlz uk uclzl jciddlg`lz
Agulgzl ige lffljuavl u}iagag` padd ml }ly|a}le fk} cliduc
ji}l ~}kvael}z
Okuaviuakg uk ijjl~u ige ao~dlolgu ~}k`}io
lffljuavldq$ agjd|eag` z|~~dq oigi`lolgu ige
jkoo|gajiuakg pauc ~}l`gigu pkolg
Lffljuavl mlcivak|} jcig`l jkoo|gajiuakg
]ly|a}lz ig |gel}zuigeag` kf ucl mi}}al}z ige
fijuk}z uciu pk|de fijadauq |~uihl ige iecl}lgjl
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
9/15
'2'
OAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}io
OAz oiul}gid ige glkgiuid cliduc ige g|u}auakg agauaiuavlz
@kid2 Elvldk~$ ao~dlolgu ige lvid|iul elokgzu}iuakg ~}kbljuz$
ag dagl pauc jk|gu}q ~}ak}aualz ige j|}}lgu ijuavaualz$ ukagj}lizl ucl jkvl}i`l ige y|idauq kf jkoo|gauq mizle
agul}vlguakgz uk ao~}kvl oiul}gid ige glkgiuid z|}vavid ige
cliduc$ lgz|}ag` ucl agjd|zakg kf i~~}k~}aiul ige aggkviuavl
g|u}auakg ige z~ljafajiddq oaj}kg|u}algu agul}vlguakgz'
5 Fkj|z jk|gu}alz2
Lucak~ai
Hlgqi
Zlgl`id Ga`l}
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
10/15
'2'
OAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige
G|u}auakg ^}k`}io
OA aelguafale ucaz iz i j}auajid k~~k}u|gauq uk agvlzu ag
}lzli}jc }ldiule uk jidja|o z|~~dlolguiuakg fk}
~}l`gigu pkolg
Oiag Kmbljuavl 2 Elvldk~ ige ulzu lvaelgjl/mizle zu}iul`alz fk}
ao~dlolguag` jidja|o z|~~dlolguiuakg e|}ag` ~}l`gigjq fk} ucl
~}lvlguakg kf ~}l/ljdio~zai ige ljdio~zai ag zluuag`z pauc dkp }iulz kf
ealui}q jidja|o aguihl ige plih cliduc zqzuloz'
\duaoiul K|ujkol2 ^kdajq oihl}z$ ~}k`}io elvldk~l}z ige oigi`l}z civl
ijj|}iul ige jko~dlul agfk}oiuakg kf ucl ~kulguaid mi}}al}z ige fijuk}z
uciu pk|de fijadauiul ao~dlolguiuakg ige ijjl~uigjl kf jidja|o ige AFI
z|~~dlolguiuakg ~}k`}ioz ige |zl uciu agfk}oiuakg uk elza`g lffljuavl
~}k`}ioz
^i}ugl}2 OA$ Jk}gldd \gavl}zauq ige ucl ~i}ugl}z agvkdvle ag OAz
elokgzu}iuakg ~}kbljuz ag Lucak~ai #Oagazu}q kf Cliduc$ Lok}q \gavl}zauq!
ige Hlgqi #Oagazu}q kf Cliduc$ IO]LF ige ]KGUK Agul}giuakgid!
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
11/15
^}kblju uk ml ao~dlolgule ag = ~cizlz uk
iee}lzz z~ljafaj jciddlg`lz fk} ~}k`}io elza`g2
$ =>>6'
Jciddlg`l 92 Dkp |~uihl kf AFI$ dkp igulgiuid ji}l jkvl}i`l ige diul ige agf}ly|lgu
jkguiju pauc cliduc ji}l zqzulo
]lzli}jc kmbljuavl 92 Uk aelguafq ig k~uao|o eldavl}q ~diufk}o fk} Ji ige AFI
z|~~dlolguiuakg mizle kg mi}}al}z ige fijadauiuag` fijuk}z fk} eldavl}q$ eloige ige
iecl}lgjl$ ige eiui kg cliduc zqzulo ji~ijauq fk} lffljuavl oigi`lolgu ige
eldavl}q kf z|~~dalz'
Jciddlg`l =2 ^kk} jko~daigjl pauc AFI z|~~dlolguiuakg j|}}lgudq$ ~kulguaiddq `}liul}
}azhz pauc ieeauakg kf jidja|o #di}`l}$ ieeauakgid uimdlu$ zael lffljuz luj'!
]lzli}jc kmbljuavl =2 Jkddlju ige izzaoadiul agfk}oiuakg kg ucl ~l}z~ljuavlz kf
cliduc ji}l ~}kvael}z ige mlglfajai}alz uciu az gllele uk elza`g lffljuavl mlcivak|}
jcig`l jkoo|gajiuakg uk z|~~k}u eloige$ ao~dlolguiuakg$ |uadariuakg$ ige
iecl}lgjl fk} Ji ige AFI z|~~dlolguiuakg']lzli}jc kmbljuavl :2 Elza`g okeldz fk} eldavl}q ige ~}kokuakg kf Ji ige AFI
z|~~dlolguz ag ~}l`gigjq' Aelguafq }loiagag` y|lzuakgz kg z|~~dlolgu eldavl}q$
u}iagag`$ olzzi`lz$ ige oiul}aidz uciu zck|de ml ulzule ag ~adku zu|eq |zag` ~}kjlzz
ige k|ujkol lvid|iuakg ige elvldk~ ~}kukjkdz fk} ~adku ~}kblju
'2'
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
12/15
I zio~dag` kf ucl azz|lz uciu padd ml iee}lzzle2
$ =>>6'
Z~ljafajiuakg kf Ji ige AFI z|~~dlolgu fk}o|diuakg
#agul}ijuakgz$ ekzag`$ ~ijhi`ag`$ jkzu$ luj! Fk}ljizuag` ige oigi`lolgu ~dig fk} lgz|}ag` iely|iul
eazu}am|uakg ige zukjhag` kf z|~~dalz
Elvldk~olgu kf ~}kukjkdz ige jcljhdazuz fk} agul`}iuag` Ji ige
AFI z|~~dlolguiuakg aguk IGJ zl}vajlz iu idd }ldlvigu dlvldz kf
ucl cliduc zqzulo
MJJ zu}iul`alz ige oiul}aidz fk} zuao|diuag` eloige iokg`
~kulguaid mlglfajai}alz$ ige okuaviuag` ige z|zuiagag` iecl}lgjl
uk z|~~dlolguz
U}iagag` fk} cliduc ji}l ~}kvael}z ag z|~~dlolgu eldavl}q igejkoo|gajiuakg
U}iagag` fk} z|~l}vazakg ige okgauk}ag` kf ao~dlolguiuakg
'2'
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
13/15
^cizl = padd agjd|el ~adku ulzuag` ucl glp
eldavl}q okeld ag mkuc jk|gu}alz
$ =>>6'
Kmbljuavl 92 Ulzu okeldz elvldk~le ag ^cizl 9 mq ao~dlolguag` Ji ige AFIz|~~dlolguiuakg paucag ucl cliduc zqzulo ag i zoidd g|oml} kf ~}kblju
zaulz zldljule ag jkgb|gjuakg pauc OKC ag Hlgqi ige Lucak~ai'
Kmbljuavl =2 Lvid|iul ucl ao~dlolguiuakg ~}kjlzz ige lffljuavlglzz kf ucl
okeld zu}iul`alz'
Kmbljuavl :2 ]lfagl okeldz ige oihl }ljkoolgeiuakgz fk} ao~}kvag`
ao~dlolguiuakg ige lffljuavlglzz'
Kmbljuavl 52 Eazzloagiul }lz|duz uk ~}kvael ~kdajq oihl}z$ ~}k`}ioelvldk~l}z ige cliduc ji}l ~}kvael}z pauc agfk}oiuakg gllele kg ucl
vid|l kf ige mlzu ~}ijuajlz fk} ao~dlolguiuakg kf Ji ige AFI
z|~~dlolguiuakg e|}ag` ~}l`gigjq'
'2'
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
14/15
Uaoldagl ige zkol ao~dajiuakgz fk} j|}}lgu ~}k`}io
lffk}uz
Ucl OA ~}kblju padd uihl uaol
Zck|de gku ao~lel ~}k`}io elvldk~olgu ag kucl}
jk|gu}alz
^}k`}ioz ag idd jk|gu}alz zck|de agvlzu ag ucl fk}oiuavl }lzli}jc
ige agfk}oiuakg jkddljuakg uciu padd lgz|}l i~~}k~}aiul
~}k`}io elza`g ag ucla} jkgulsu2
Aggkviuavl idul}giuavlz fk} eldavl}q #~i}uaj|di}dq af AFI
~}k`}ioz civl gku mllg z|jjlzzf|d!
Aelguafajiuakg ige }lzkd|uakg kf fk}ljizuag` ige z|~~dq jciag
azz|lz
Lffljuavl u}iagag` fk} cliduc ji}l ~}kvael}z
]ldlvigu ige lffljuavl jkoo|gajiuakg uk ~}kokul ~}k`}io
|~uihl ige |uadariuakg mq ~}l`gigu pkolg
-
7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs
15/15